AN
MCID: ACN002
MIFTS: 60

Acanthosis Nigricans (AN)

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Acanthosis Nigricans

MalaCards integrated aliases for Acanthosis Nigricans:

Name: Acanthosis Nigricans 56 12 74 52 29 54 6 43 15 17 71 32
an - Acanthosis Nigricans 12
Keratosis Nigricans 12
an 52

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
acanthosis nigricans:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:3138
OMIM 56 100600
MeSH 43 D000052
NCIt 49 C26687
SNOMED-CT 67 402599005
ICD10 32 L83
MedGen 41 C0000889
SNOMED-CT via HPO 68 263681008 72129000
UMLS 71 C0000889

Summaries for Acanthosis Nigricans

NIH Rare Diseases : 52 Acanthosis nigricans (AN) is a skin disorder in which there is darker, thick, velvety skin in body folds and creases. This condition usually appears slowly and doesn't cause any symptoms other than skin changes. Eventually, dark, velvety skin with very visible markings and creases appears in the armpits, groin and neck folds, and over the joints of the fingers and toes. Less commonly, the lips, palms, soles of the feet, or other areas may be affected. The exact cause of this condition is not well understood; but it can be inherited or related to medical problems such as obesity, diabetes mellitus (insulin- resistance), some prescription drugs, and cancer .

MalaCards based summary : Acanthosis Nigricans, also known as an - acanthosis nigricans, is related to pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities and acquired generalized lipodystrophy, and has symptoms including pruritus An important gene associated with Acanthosis Nigricans is PRMT7 (Protein Arginine Methyltransferase 7), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Letrozole and Metformin have been mentioned in the context of this disorder. Affiliated tissues include skin, ovary and lung, and related phenotypes are acanthosis nigricans and growth/size/body region

Wikipedia : 74 Acanthosis nigricans is a medical sign characterised by brown-to-black, poorly defined, velvety... more...

More information from OMIM: 100600

Related Diseases for Acanthosis Nigricans

Diseases related to Acanthosis Nigricans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 13231)
# Related Disease Score Top Affiliating Genes
1 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 33.3 INSR INS IGF1
2 acquired generalized lipodystrophy 32.6 LMNA LEP ADIPOQ
3 donohue syndrome 32.3 INSR INS IGF1R IGF1 BAIAP2L1
4 congenital generalized lipodystrophy 32.3 PPARG LMNA LEP INS
5 familial partial lipodystrophy 31.9 PPARG LMNA LEP INS ADIPOQ
6 lipodystrophy, congenital generalized, type 1 31.7 PPARG LMNA LEP INS ADIPOQ
7 eating disorder 31.6 LEP GH1 ADIPOQ
8 bulimia nervosa 31.5 PRL LEP INS
9 plagiocephaly 31.4 FGFR3 FGFR2
10 arteries, anomalies of 31.4 PPARG LEP INS ADIPOQ
11 nontuberculous mycobacterial lung disease 31.2 LEP ADIPOQ
12 laron syndrome 31.2 IGF1 GH1 ADIPOQ
13 gigantism 31.2 PRL GH1
14 hyperinsulinemic hypoglycemia 31.2 INSR INS IGF1R
15 uremia 31.2 LEP INS GH1
16 bone resorption disease 31.2 PPARG LEP INS IGF1
17 lysosomal storage disease 31.1 PPARG LEP INS ADIPOQ
18 fibromyalgia 31.1 PRL LEP IGF1
19 achondroplasia 31.1 IGF1 FGFR3 FGFR2
20 fgfr craniosynostosis syndromes 31.1 FGFR3 FGFR2
21 secondary adrenal insufficiency 31.1 INS IGF1
22 mammographic density 31.1 PRL IGF1
23 exophthalmos 31.0 PRL FGFR3 FGFR2
24 central precocious puberty 31.0 IGF1 GH1
25 adermatoglyphia 31.0 INS IGF1 GH1
26 hypothyroidism, congenital, nongoitrous, 4 31.0 PRL GH1
27 apnea, obstructive sleep 31.0 LEP INS IGF1 ADIPOQ
28 pseudohypoparathyroidism, type ia 31.0 PRL IGF1 GH1
29 short bowel syndrome 30.9 LEP IGF1 GH1
30 lipodystrophy, familial partial, type 2 30.9 SLC2A4 PPARG LMNA LEP INS FNDC5
31 syndromic craniosynostosis 30.9 FGFR3 FGFR2
32 anorexia nervosa 30.9 SHBG PRL LEP INS IGF1 GH1
33 fibrous dysplasia 30.9 PRL IGF1 GH1
34 lipodystrophy, congenital generalized, type 2 30.9 PPARG LMNA LEP
35 primary hyperparathyroidism 30.9 PRL INS IGF1
36 chronic kidney disease 30.9 LEP INS IGF1 ALMS1 ADIPOQ
37 islet cell tumor 30.9 INS IGF1 GH1
38 intracranial hypertension, idiopathic 30.9 LEP IGF1 GH1
39 impotence 30.9 SHBG PRL INS
40 empty sella syndrome 30.8 PRL INS IGF1 GH1
41 mccune-albright syndrome 30.8 PRL LEP IGF1 GH1
42 maturity-onset diabetes of the young, type 1 30.8 PPARG LEP INS ADIPOQ
43 septooptic dysplasia 30.7 PRL IGF1 GH1
44 non-alcoholic fatty liver disease 30.7 SLC2A4 PPARG LEP INSR INS ADIPOQ
45 hyperuricemia 30.7 PPARG LEP INS
46 pituitary gland disease 30.7 PRL INS IGF1 GH1
47 bone disease 30.7 IGF1R IGF1 FGFR3 FGFR2
48 craniopharyngioma 30.7 PRL INS IGF1 GH1
49 fetal macrosomia 30.7 LEP INSR INS IGF1
50 familial hyperlipidemia 30.7 PRMT7 PPARG LEP INS ADIPOQ

Graphical network of the top 20 diseases related to Acanthosis Nigricans:



Diseases related to Acanthosis Nigricans

Symptoms & Phenotypes for Acanthosis Nigricans

Human phenotypes related to Acanthosis Nigricans:

31
# Description HPO Frequency HPO Source Accession
1 acanthosis nigricans 31 HP:0000956

Symptoms via clinical synopsis from OMIM:

56
Skin:
benign acanthosis nigricans
thick hyperpigmented flexural area skin

Clinical features from OMIM:

100600

UMLS symptoms related to Acanthosis Nigricans:


pruritus

MGI Mouse Phenotypes related to Acanthosis Nigricans:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.46 ADIPOQ ALMS1 BAIAP2L1 ELOVL1 FGFR2 FGFR3
2 homeostasis/metabolism MP:0005376 10.45 ADIPOQ ALMS1 BAIAP2L1 ELOVL1 FGFR2 FGFR3
3 cellular MP:0005384 10.43 ADIPOQ ALMS1 FGFR2 FGFR3 IGF1 IGF1R
4 adipose tissue MP:0005375 10.41 ADIPOQ ALMS1 FGFR2 IGF1 IGF1R INS
5 endocrine/exocrine gland MP:0005379 10.41 ADIPOQ ALMS1 FGFR2 IGF1 IGF1R INS
6 cardiovascular system MP:0005385 10.4 ADIPOQ BAIAP2L1 FGFR2 IGF1 IGF1R INS
7 immune system MP:0005387 10.39 ADIPOQ ALMS1 FGFR2 FGFR3 IGF1 IGF1R
8 hematopoietic system MP:0005397 10.31 ADIPOQ FGFR2 FGFR3 IGF1 IGF1R INS
9 mortality/aging MP:0010768 10.28 ADIPOQ BAIAP2L1 ELOVL1 FGFR2 FGFR3 IGF1
10 integument MP:0010771 10.27 ADIPOQ ELOVL1 FGFR2 FGFR3 IGF1 IGF1R
11 liver/biliary system MP:0005370 10.23 ADIPOQ ALMS1 FGFR2 IGF1R INS INSR
12 digestive/alimentary MP:0005381 10.18 FGFR2 FGFR3 IGF1R INS INSR LEP
13 muscle MP:0005369 10.18 ADIPOQ FGFR2 IGF1 IGF1R INS INSR
14 nervous system MP:0003631 10.17 ADIPOQ ALMS1 FGFR2 FGFR3 IGF1 IGF1R
15 hearing/vestibular/ear MP:0005377 10.09 ALMS1 FGFR2 FGFR3 IGF1 IGF1R LMNA
16 limbs/digits/tail MP:0005371 10.02 BAIAP2L1 FGFR2 FGFR3 IGF1 IGF1R LEP
17 neoplasm MP:0002006 10.02 ADIPOQ FGFR2 FGFR3 IGF1 IGF1R LEP
18 renal/urinary system MP:0005367 9.96 ADIPOQ ALMS1 FGFR2 FGFR3 IGF1 INS
19 reproductive system MP:0005389 9.93 ALMS1 FGFR2 FGFR3 IGF1 IGF1R INS
20 respiratory system MP:0005388 9.56 ADIPOQ FGFR2 FGFR3 IGF1 IGF1R INSR
21 skeleton MP:0005390 9.36 ADIPOQ FGFR2 FGFR3 FNDC5 IGF1 IGF1R

Drugs & Therapeutics for Acanthosis Nigricans

Drugs for Acanthosis Nigricans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
2
Metformin Approved Phase 3 657-24-9 14219 4091
3
Rosiglitazone Approved, Investigational Phase 3 122320-73-4 77999
4 Hormone Antagonists Phase 3
5 Hormones Phase 3
6 Estrogen Antagonists Phase 3
7 Estrogen Receptor Antagonists Phase 3
8 Estrogens Phase 3
9 Aromatase Inhibitors Phase 3
10 Hypoglycemic Agents Phase 3
11 Autoantibodies Phase 3
12
Leuprolide Approved, Investigational Phase 2 53714-56-0 657181 3911
13
Spironolactone Approved Phase 2 52-01-7, 1952-01-7 5833
14
Sodium citrate Approved, Investigational Phase 2 68-04-2
15
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
16
Enclomiphene Investigational Phase 2 15690-57-0
17 Mineralocorticoids Phase 2
18 Antineoplastic Agents, Hormonal Phase 2
19 Mineralocorticoid Receptor Antagonists Phase 2
20 diuretics Phase 2
21 Diuretics, Potassium Sparing Phase 2
22 Clomiphene Phase 2
23 Zuclomiphene Phase 2
24 Citrate Phase 2
25
Paroxetine Approved, Investigational 61869-08-7 43815
26
Fluoxetine Approved, Vet_approved 54910-89-3 3386
27
Sertraline Approved 79617-96-2 68617
28
Glycolic acid Approved, Investigational 79-14-1 757
29
Melatonin Approved, Nutraceutical, Vet_approved 73-31-4 896
30
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved 65-23-6 1054
31 Vitamins
32 Vitamin B 6
33 Antioxidants
34 Vitamin B Complex
35 Protective Agents
36 Calcium, Dietary
37 Antidepressive Agents
38 Dermatologic Agents
39 Keratolytic Agents
40 Insulin, Globin Zinc
41 insulin
42
Pyridoxal Experimental, Nutraceutical 66-72-8 1050
43
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
2 Efficacy of Combined Letrozole-metformin in Comparison With Letrozole Only in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome Unknown status NCT03135301 Phase 3 letrozole plus metformin;letrozole
3 Glycemic Control in Children and Adolescents With Double Diabetes: Trial of Optimized Insulin-Metformin Regimen Completed NCT01334125 Phase 3 Metformin;Placebo
4 Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial Completed NCT00081328 Phase 3 Metformin;Rosiglitazone
5 Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome Completed NCT00004311 Phase 2 leuprolide acetate;spironolactone
6 Insulin Sensitizing Agent (Metformin) Improves Clinical Pregnancy Rate and Insulin Parameters in Polycystic Ovarian Syndrome Patients With Acanthosis Nigricans Completed NCT02562664 Phase 2 CC;Placebo tablets;Metformin
7 Prevalence of Carbohydrate Intolerance in Lean and Obese Children Unknown status NCT00000112
8 Spectroscopic and Colorimetric Analysis of Acanthosis Nigricans in Patients With Hyperinsulinemia Completed NCT01125150 Metformin
9 Effect of Melatonin on Body Composition, Glucose Metabolism and Lipid Metabolism Completed NCT02604095
10 Children's Healthy Living Program for Remote Underserved Minority Populations in the Pacific Region Completed NCT01881373
11 Repercussion of Maternal Lifestyle on Obstetric and Neonatal Outcomes Completed NCT01409382
12 PACE-iDP: An Intervention for Youth at Risk for Diabetes Completed NCT00412165
13 Prevalence of Hirsutism in Turkey: Data of The Dermatoendocrinology Study Group Recruiting NCT04292587
14 Impact of a Physical Rehabilitation Program on the Quality of Life of Patients With Acromegaly: a Non-randomized Clinical Trial. Recruiting NCT03710499
15 Use Of A Novel Quantitative Tool For Evaluation of Pseudo- Acanthosis Nigricans: Acanthosis Nigricans Area And Severity Index Active, not recruiting NCT04359485
16 Prevalence of Carbohydrate Intolerance in Lean and Overweight/Obese Children Active, not recruiting NCT01967849
17 Studying the Effect of Mediterranean Diet on Insulin Resistance Compared to the Regular Diet Among Obese Children and Adolescents Aged 10-16 Years. Enrolling by invitation NCT04313452

Search NIH Clinical Center for Acanthosis Nigricans

Cochrane evidence based reviews: acanthosis nigricans

Genetic Tests for Acanthosis Nigricans

Genetic tests related to Acanthosis Nigricans:

# Genetic test Affiliating Genes
1 Acanthosis Nigricans 29

Anatomical Context for Acanthosis Nigricans

MalaCards organs/tissues related to Acanthosis Nigricans:

40
Skin, Ovary, Lung, Liver, Thyroid, Breast, Bone

Publications for Acanthosis Nigricans

Articles related to Acanthosis Nigricans:

(show top 50) (show all 1958)
# Title Authors PMID Year
1
Genetic basis of acanthosis nigricans in Mexican Americans and its association with phenotypes related to type 2 diabetes. 56 61 54
10914675 2000
2
Familial acanthosis nigricans with madarosis. 61 56
7669619 1995
3
Autosomal dominant insulin resistance syndrome due to postbinding defect. 61 56
1282780 1992
4
Familial acanthosis nigricans. 61 56
6486848 1984
5
[Contribution to the clinical picture of benign familial acanthosis nigricans]. 56 61
5826935 1965
6
[Genetic pathology of acanthosis nigricans]. 56 61
13312473 1955
7
Review of the recently defined molecular mechanisms underlying thanatophoric dysplasia and their potential therapeutic implications for achondroplasia. 61 54
20034074 2010
8
Alterations of carbohydrate and lipoprotein metabolism in childhood obesity--impact of insulin resistance and acanthosis nigricans. 54 61
20333871 2009
9
[Fatty liver disease, insulin resistance and adiponectin in an obese pediatric population]. 54 61
19850541 2009
10
Prevalence of acanthosis nigricans and its correlates in a cross-section of Nigerians with type 2 diabetes mellitus. 61 54
19762579 2009
11
Acanthosis nigricans and insulin sensitivity in patients with achondroplasia and hypochodroplasia due to FGFR3 mutations. 61 54
19622626 2009
12
FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies. 54 61
19387476 2009
13
Type B insulin resistance in a systemic lupus erythematosus patient. 61 54
20374339 2009
14
Evaluation of insulin resistance in obese women with and without acanthosis nigricans. 61 54
19348659 2009
15
Cardiometabolic risk among African American women: a pilot study. 54 61
19242280 2009
16
Malignant acanthosis nigricans with enhanced expression of fibroblast growth factor receptor 3. 54 61
19688170 2009
17
Paraneoplastic acanthosis nigricans and silent meningioma producing transforming growth factor-alpha. 54 61
19049942 2008
18
Clearance of acanthosis nigricans associated with insulinoma following surgical resection. 61 54
18669553 2008
19
Screening of glucose/insulin metabolic alterations in men with multiple skin tags on the neck. 61 54
18397315 2008
20
Hypochondroplasia and Acanthosis nigricans: a new syndrome due to the p.Lys650Thr mutation in the fibroblast growth factor receptor 3 gene? 61 54
18583390 2008
21
Prevalence of insulin resistance and its association with metabolic syndrome criteria among Bolivian children and adolescents with obesity. 61 54
18700035 2008
22
Body shape and size and insulin resistance as early clinical predictors of hyperandrogenic anovulation in ethnic minority adolescent girls. 54 61
18639784 2008
23
Treatment options in insulin resistance obesity-related acanthosis nigricans. 54 61
18492785 2008
24
Insulin receptor autoimmunity and insulin resistance. 54 61
18556968 2008
25
Can adiponectin predict abnormal glucose tolerance in Thai women with polycystic ovary syndrome? 61 54
18226130 2008
26
Acanthosis nigricans in a child with mild osteochondrodysplasia and K650Q mutation in the FGFR3 gene. 61 54
18000903 2007
27
The heterozygous LMNA mutation p.R471G causes a variable phenotype with features of two types of familial partial lipodystrophy. 54 61
18041775 2007
28
Crouzon with acanthosis nigricans. Further delineation of the syndrome. 61 54
17935505 2007
29
Is Acanthosis Nigricans a reliable indicator for risk of type 2 diabetes? 61 54
17894521 2007
30
Familial acanthosis nigricans due to K650T FGFR3 mutation. 61 54
17875876 2007
31
Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1. 54 61
17561467 2007
32
Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. 61 54
17426408 2007
33
High frequency of FGFR3 mutations in adenoid seborrheic keratoses. 61 54
16778799 2006
34
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. 61 54
16841094 2006
35
Atypical localization of acanthosis nigricans in an obese patient with increased leptin level: is there an association? 54 61
16843127 2006
36
Influence of skin color on the diagnostic utility of clinical acanthosis nigricans to predict insulin resistance in obese patients. 54 61
16824934 2006
37
Screening for type 2 diabetes in children with acanthosis nigricans. 61 54
16873592 2006
38
Transmembrane helix heterodimerization in lipid bilayers: probing the energetics behind autosomal dominant growth disorders. 54 61
16500676 2006
39
FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. 61 54
16384584 2006
40
[Metabolic syndrome in childhood and adolescence]. 54 61
16610614 2006
41
Androgen excess disorders in women: the severe insulin-resistant hyperandrogenic syndrome, HAIR-AN. 61 54
16435040 2006
42
Acanthosis Nigricans, insulin resistance (HOMA) and dyslipidemia among Native American children. 61 54
16499154 2006
43
African American women, metabolic syndrome, and national cholesterol education program criteria: a pilot study. 61 54
16224320 2005
44
Clinical presentation of type 2 diabetes mellitus in children and adolescents. 54 61
16385761 2005
45
Type A insulin resistance syndrome revealing a novel lamin A mutation. 54 61
15919811 2005
46
Insulin resistance and impaired glucose tolerance in obese children and adolescents referred to a tertiary-care center in Israel. 54 61
15889115 2005
47
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 54 61
15772091 2005
48
Acanthosis nigricans in association with congenital adrenal hyperplasia: resolution after treatment. Case report. 61 54
16052863 2005
49
Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. 54 61
15623819 2005
50
Insulin resistance in obese adolescents. 54 61
16302580 2005

Variations for Acanthosis Nigricans

ClinVar genetic disease variations for Acanthosis Nigricans:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PRMT7 NM_019023.5(PRMT7):c.1713C>A (p.Cys571Ter)SNV Pathogenic 523434 rs1251713297 16:68389688-68389688 16:68355785-68355785
2 PRMT7 NM_019023.5(PRMT7):c.322G>T (p.Glu108Ter)SNV Pathogenic/Likely pathogenic 523435 rs1014959895 16:68363008-68363008 16:68329105-68329105
3 FGFR3 NM_001163213.1(FGFR3):c.1949A>C (p.Tyr650Ser)SNV Likely pathogenic 376699 rs587779383 4:1807884-1807884 4:1806157-1806157
4 FGFR3 NM_001163213.1(FGFR3):c.1954A>C (p.Lys652Gln)SNV Conflicting interpretations of pathogenicity 16348 rs78311289 4:1807889-1807889 4:1806162-1806162
5 46;Y;inv(X)(q27q28)inversion Uncertain significance 267831

Expression for Acanthosis Nigricans

Search GEO for disease gene expression data for Acanthosis Nigricans.

Pathways for Acanthosis Nigricans

Pathways related to Acanthosis Nigricans according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.67 SLC2A4 PRL LEP INSR INS IGF1R
2
Show member pathways
13.52 PRL INSR INS IGF1R IGF1 GH1
3
Show member pathways
13.38 SLC2A4 INSR IGF1R IGF1 GH1 FGFR3
4
Show member pathways
13.03 INSR INS IGF1R IGF1 GH1 FGFR3
5
Show member pathways
12.9 SLC2A4 INSR INS IGF1R IGF1 GH1
6
Show member pathways
12.87 PRL INSR INS IGF1R IGF1 GH1
7
Show member pathways
12.86 SLC2A4 INSR IGF1R IGF1 FGFR3 FGFR2
8
Show member pathways
12.84 PPARG INS IGF1R IGF1 FGFR2
9 12.81 PPARG IGF1R IGF1 FGFR3 FGFR2
10
Show member pathways
12.76 SLC2A4 LEP INSR INS ADIPOQ
11 12.74 INSR INS IGF1R IGF1 FGFR3 FGFR2
12
Show member pathways
12.71 INSR INS IGF1R IGF1 FGFR3 FGFR2
13
Show member pathways
12.52 TBC1D4 SLC2A4 INSR INS IGF1R
14
Show member pathways
12.46 INSR INS IGF1R IGF1 FGFR3 FGFR2
15
Show member pathways
12.45 PRL LEP INS GH1
16
Show member pathways
12.41 INSR IGF1R FGFR3 FGFR2
17 12.4 TBC1D4 SLC2A4 PPARG INSR INS IGF1R
18
Show member pathways
12.39 INSR IGF1R IGF1 GH1 FGFR3 FGFR2
19
Show member pathways
12.3 PPARG INSR IGF1R IGF1
20
Show member pathways
12.27 IGF1R IGF1 GH1 FGFR3 FGFR2
21
Show member pathways
12.23 LEP INS IGF1 GH1
22
Show member pathways
12.22 SLC2A4 PPARG LEP INSR INS IGF1R
23
Show member pathways
12.21 TBC1D4 LMNA INSR IGF1R FGFR3 FGFR2
24
Show member pathways
12.2 SLC2A4 LEP INSR INS
25 12.13 INSR IGF1R FGFR3 FGFR2
26 12.11 IGF1R IGF1 FGFR3 FGFR2
27
Show member pathways
12.01 SLC2A4 INSR INS IGF1R IGF1
28
Show member pathways
11.98 PPARG INSR INS IGF1R IGF1 ADIPOQ
29
Show member pathways
11.97 TBC1D4 SLC2A4 INSR INS
30 11.96 INSR INS IGF1R IGF1
31
Show member pathways
11.87 SLC2A4 INSR INS ADIPOQ
32 11.71 SLC2A4 PPARG LEP INS IGF1 ADIPOQ
33 11.7 INSR IGF1R IGF1 GH1 FGFR3 FGFR2
34 11.69 SLC2A4 LEP ADIPOQ
35 11.67 IGF1R IGF1 GH1 FGFR3
36 11.53 INSR INS IGF1R IGF1
37 11.49 PRL LEP INSR INS
38 11.41 INSR IGF1R FGFR3 FGFR2
39 11.39 INSR INS IGF1
40 11.35 SLC2A4 PPARG LMNA LEP INS IGF1
41 11.19 PPARG LEP ADIPOQ
42 11.17 TBC1D4 SLC2A4 INSR INS
43 11.05 PRL LEP INS
44 11.01 INSR IGF1R IGF1 GH1 FGFR3 FGFR2
45
Show member pathways
10.95 TBC1D4 SLC2A4 INSR
46 10.7 SLC2A4 PPARG LEP INSR ADIPOQ

GO Terms for Acanthosis Nigricans

Cellular components related to Acanthosis Nigricans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 SHBG PRL LEP INS IGF1 GH1
2 receptor complex GO:0043235 9.62 INSR IGF1R FGFR3 FGFR2
3 insulin receptor complex GO:0005899 9.26 INSR IGF1R
4 alphav-beta3 integrin-IGF-1-IGF1R complex GO:0035867 8.96 IGF1R IGF1
5 endosome lumen GO:0031904 8.8 PRL INS GH1

Biological processes related to Acanthosis Nigricans according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.27 PRL PPARG LEP INS IGF1R IGF1
2 positive regulation of cell proliferation GO:0008284 10.01 PRL LEP INSR INS IGF1R IGF1
3 positive regulation of cell migration GO:0030335 9.97 INSR INS IGF1R IGF1
4 protein autophosphorylation GO:0046777 9.92 INSR IGF1R FGFR3 FGFR2
5 peptidyl-tyrosine phosphorylation GO:0018108 9.89 INSR IGF1R FGFR3 FGFR2
6 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.88 INSR IGF1R FGFR3 FGFR2
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.86 IGF1 GH1 ADIPOQ
8 insulin receptor signaling pathway GO:0008286 9.85 INSR INS IGF1R
9 response to nutrient GO:0007584 9.85 PPARG LEP ADIPOQ
10 response to ethanol GO:0045471 9.85 SLC2A4 LEP FGFR2 ADIPOQ
11 positive regulation of protein kinase B signaling GO:0051897 9.85 LEP INSR INS IGF1R FGFR3 FGFR2
12 cellular response to retinoic acid GO:0071300 9.82 PPARG LEP FGFR2
13 glucose metabolic process GO:0006006 9.81 LEP INS ADIPOQ
14 positive regulation of cold-induced thermogenesis GO:0120162 9.81 LEP IGF1R ALMS1 ADIPOQ
15 positive regulation of kinase activity GO:0033674 9.8 INSR IGF1R FGFR3 FGFR2
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 LEP IGF1 GH1 FGFR3
17 activation of protein kinase B activity GO:0032148 9.74 INSR INS IGF1
18 positive regulation of JAK-STAT cascade GO:0046427 9.73 PRL LEP GH1
19 positive regulation of glucose import GO:0046326 9.73 INSR INS IGF1 ADIPOQ
20 cellular response to insulin stimulus GO:0032869 9.73 TBC1D4 SLC2A4 PPARG LEP INSR ADIPOQ
21 response to nutrient levels GO:0031667 9.72 PRL PPARG LEP GH1 ADIPOQ
22 positive regulation of mitotic nuclear division GO:0045840 9.71 INSR INS IGF1
23 positive regulation of glycolytic process GO:0045821 9.7 INSR INS IGF1
24 amyloid-beta clearance GO:0097242 9.69 INSR IGF1R
25 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.69 PRL GH1
26 insulin-like growth factor receptor signaling pathway GO:0048009 9.69 IGF1R IGF1
27 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.68 IGF1 GH1
28 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.68 PPARG ADIPOQ
29 neuron projection maintenance GO:1990535 9.67 INSR INS
30 dendritic spine maintenance GO:0097062 9.66 INSR IGF1R
31 regulation of protein localization to nucleus GO:1900180 9.66 LMNA LEP
32 positive regulation of phospholipase activity GO:0010518 9.65 FGFR3 FGFR2
33 endochondral bone growth GO:0003416 9.65 FGFR3 FGFR2
34 positive regulation of glycogen biosynthetic process GO:0045725 9.65 INSR INS IGF1
35 negative regulation of acute inflammatory response GO:0002674 9.64 PPARG INS
36 positive regulation of respiratory burst GO:0060267 9.63 INSR INS
37 bone mineralization involved in bone maturation GO:0035630 9.63 LEP IGF1
38 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.63 LEP INSR INS IGF1R IGF1 GH1
39 positive regulation of developmental growth GO:0048639 9.61 LEP INSR
40 positive regulation of fatty acid metabolic process GO:0045923 9.61 PPARG ADIPOQ
41 positive regulation of protein complex disassembly GO:0043243 9.6 INSR IGF1R
42 bone maturation GO:0070977 9.58 GH1 FGFR3
43 positive regulation of MAPK cascade GO:0043410 9.5 LEP INSR INS IGF1R IGF1 FGFR3
44 glucose homeostasis GO:0042593 9.17 SLC2A4 PPARG LEP INSR INS IGF1R

Molecular functions related to Acanthosis Nigricans according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.3 TBC1D4 SLC2A4 SHBG PRMT7 PRL PPARG
2 protein tyrosine kinase activity GO:0004713 9.71 INSR IGF1R FGFR3 FGFR2
3 insulin-like growth factor I binding GO:0031994 9.51 INSR IGF1R
4 insulin receptor substrate binding GO:0043560 9.49 INSR IGF1R
5 insulin binding GO:0043559 9.48 INSR IGF1R
6 fibroblast growth factor-activated receptor activity GO:0005007 9.46 FGFR3 FGFR2
7 insulin-activated receptor activity GO:0005009 9.43 INSR IGF1R
8 insulin receptor binding GO:0005158 9.43 INS IGF1R IGF1
9 prolactin receptor binding GO:0005148 9.37 PRL GH1
10 insulin-like growth factor receptor binding GO:0005159 9.33 INSR INS IGF1
11 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.26 INSR IGF1R FGFR3 FGFR2
12 hormone activity GO:0005179 9.17 PRL LEP INS IGF1 GH1 FNDC5

Sources for Acanthosis Nigricans

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....